• Bicycle Therapeutics’ third-quarter 2026 net loss narrowed 82% year over year to $10.48 million.
• Collaboration revenue more than doubled year over year to $34.06 million, primarily due to recognition of remaining amounts under the terminated Bayer agreement.
• Cash and cash equivalents totaled $469.9 million at September 30, 2026, with expected cash runway into 2030.
• Nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer; further updates are expected in 2027.
• The first company-sponsored radioligand clinical trial for BT1702 is expected to begin in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610290700BIZWIRE_USPR_____20261029_BW336969) on October 29, 2026, and is solely responsible for the information contained therein.